699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC)

Jeffrey Clarke, George R. Simon, Lin Gu et al.|Regular and Young Investigator Award Abstracts|2022

Cited by 1